Relmada Therapeutics, Inc.
RLMD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001553643
In the last 90 days, Relmada Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $693.7M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Relmada Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- +16 vs. Q4 2021
- Shares held
- 23.1M
- +2.34M (+11.3%) vs. Q4 2021
- Total value
- $623.1M
- +$155.9M (+33.4%) vs. Q4 2021
- New holders
- 29
- 41 more added
- Sold out
- 13
- 21 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RLMD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 126 | $693.7M |
| Q1 2026 | 103 | $588.8M |
| Q4 2025 | 78 | $245.8M |
| Q3 2025 | 44 | $15.5M |
| Q2 2025 | 50 | $3.18M |
| Q1 2025 | 44 | $1.68M |
| Q4 2024 | 48 | $4.36M |
| Q3 2024 | 69 | $40.2M |
| Q2 2024 | 79 | $40.7M |
| Q1 2024 | 93 | $66.5M |
| Q4 2023 | 83 | $56.4M |
| Q3 2023 | 88 | $45.0M |
| Q2 2023 | 95 | $39.7M |
| Q1 2023 | 91 | $40.3M |
| Q4 2022 | 110 | $66.8M |
| Q3 2022 | 134 | $953.6M |
| Q2 2022 | 113 | $468.5M |
| Q1 2022 | 113 | $623.1M |
| Q4 2021 | 97 | $467.2M |
| Q3 2021 | 87 | $262.8M |
| Q2 2021 | 85 | $318.3M |
| Q1 2021 | 82 | $335.7M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Relmada Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 495,113 | $13.4M | 0.08% | 00.0% | Unchanged |
| Parsons Capital Management Inc | 503,076 | $13.6M | 1.03% | −336−0.1% | Reduced |
| Vivo Capital, LLC | 705,882 | $19.1M | 1.31% | −176,470−20.0% | Reduced |
| Great Point Partners LLC | 790,000 | $21.3M | 5.16% | +72,680+10.1% | Added |
| Citadel Advisors LLC | 939,472 | $25.4M | 0.03% | +645,518+219.6% | Added |
| Cowen and Company, LLC | 1,164,361 | $31.4M | 3.17% | +1,014,587+677.4% | Added |
| Point72 Asset Management, L.P. | 1,312,400 | $35.4M | 0.16% | +366,087+38.7% | Added |
| Vanguard Group Inc | 1,324,014 | $35.7M | 0.00% | +99,113+8.1% | Added |
| BVF Inc | 1,647,400 | $44.5M | 1.78% | 00.0% | Unchanged |
| BlackRock Inc. | 1,952,808 | $52.7M | 0.00% | +567,573+41.0% | Added |
| Ra Capital Management, L.P. | 2,000,000 | $54.0M | 1.18% | 00.0% | Unchanged |
| VR Adviser, LLC | 2,270,072 | $61.3M | 9.93% | 00.0% | Unchanged |
| RTW Investments, LP | 2,540,074 | $68.6M | 1.42% | +353,750+16.2% | Added |
| Avidity Partners Management LP | 0 | $0 | 0.00% | −731,536−100.0% | Sold out |
| Logos Global Management LP | 0 | $0 | 0.00% | −400,000−100.0% | Sold out |
| Norges Bank | 0 | $0 | 0.00% | −98,500−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −91,500−100.0% | Sold out |
| Tang Capital Management LLC | 0 | $0 | 0.00% | −59,122−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −54,800−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −23,255−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −17,429−100.0% | Sold out |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −14,400−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −9,143−100.0% | Sold out |
| Knott David M Jr | 0 | $0 | 0.00% | −6,000−100.0% | Sold out |
| Massmutual Trust Co FSB | 0 | $0 | 0.00% | −28−100.0% | Sold out |